These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 29681156)
21. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. Borrmann T; Hinz S; Bertarelli DC; Li W; Florin NC; Scheiff AB; Müller CE J Med Chem; 2009 Jul; 52(13):3994-4006. PubMed ID: 19569717 [TBL] [Abstract][Full Text] [Related]
22. Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands. Baker JG; Middleton R; Adams L; May LT; Briddon SJ; Kellam B; Hill SJ Br J Pharmacol; 2010 Feb; 159(4):772-86. PubMed ID: 20105183 [TBL] [Abstract][Full Text] [Related]
23. Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A Barresi E; Giacomelli C; Daniele S; Tonazzini I; Robello M; Salerno S; Piano I; Cosimelli B; Greco G; Da Settimo F; Martini C; Trincavelli ML; Taliani S Bioorg Med Chem; 2018 Dec; 26(22):5885-5895. PubMed ID: 30415894 [TBL] [Abstract][Full Text] [Related]
24. Molecular modeling approaches for the discovery of adenosine A Deb PK; Chandrasekaran B; Mailavaram R; Tekade RK; Jaber AMY Drug Discov Today; 2019 Sep; 24(9):1854-1864. PubMed ID: 31103731 [TBL] [Abstract][Full Text] [Related]
25. New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides. Inamdar GS; Pandya AN; Thakar HM; Sudarsanam V; Kachler S; Sabbadin D; Moro S; Klotz KN; Vasu KK Eur J Med Chem; 2013 May; 63():924-34. PubMed ID: 23685887 [TBL] [Abstract][Full Text] [Related]
31. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists. Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167 [TBL] [Abstract][Full Text] [Related]
32. Exploring the structural determinants of novel xanthine derivatives as A Yang Y; Li Y; Zhou W; Chen Y; Wu Q; Pan Y; Zhang S; Yang L J Biomol Struct Dyn; 2019 Aug; 37(13):3467-3481. PubMed ID: 30175951 [TBL] [Abstract][Full Text] [Related]
33. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A Mallo-Abreu A; Prieto-Díaz R; Jespers W; Azuaje J; Majellaro M; Velando C; García-Mera X; Caamaño O; Brea J; Loza MI; Gutiérrez-de-Terán H; Sotelo E J Med Chem; 2020 Jul; 63(14):7721-7739. PubMed ID: 32573250 [TBL] [Abstract][Full Text] [Related]
34. A patent review of adenosine A Francucci B; Dal Ben D; Lambertucci C; Spinaci A; Volpini R; Marucci G; Buccioni M Expert Opin Ther Pat; 2022 Jun; 32(6):689-712. PubMed ID: 35387537 [TBL] [Abstract][Full Text] [Related]
35. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists. Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777 [TBL] [Abstract][Full Text] [Related]
36. The A Mølck C; Ryall J; Failla LM; Coates JL; Pascussi JM; Heath JK; Stewart G; Hollande F Cancer Lett; 2016 Dec; 383(1):135-143. PubMed ID: 27693637 [TBL] [Abstract][Full Text] [Related]
37. Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A Vlachodimou A; de Vries H; Pasoli M; Goudswaard M; Kim SA; Kim YC; Scortichini M; Marshall M; Linden J; Heitman LH; Jacobson KA; IJzerman AP Biochem Pharmacol; 2022 Jun; 200():115027. PubMed ID: 35395239 [TBL] [Abstract][Full Text] [Related]
38. Exploring Biginelli-based scaffolds as A Prieto-Díaz R; Fojo-Carballo H; Majellaro M; Tandarić T; Azuaje J; Brea J; Loza MI; Barbazán J; Salort G; Chotalia M; Rodríguez-Pampín I; Mallo-Abreu A; Rita Paleo M; García-Mera X; Ciruela F; Gutiérrez-de-Terán H; Sotelo E Biomed Pharmacother; 2024 Apr; 173():116345. PubMed ID: 38442670 [TBL] [Abstract][Full Text] [Related]
39. [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors. Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Moorman AR; Gessi S; Merighi S; Varani K; Borea PA Bioorg Med Chem Lett; 2004 Jul; 14(13):3607-10. PubMed ID: 15177484 [TBL] [Abstract][Full Text] [Related]
40. PSB 603 - a known selective adenosine A2B receptor antagonist - has anti-inflammatory activity in mice. Kotańska M; Szafarz M; Mika K; Dziubina A; Bednarski M; Müller CE; Sapa J; Kieć-Kononowicz K Biomed Pharmacother; 2021 Mar; 135():111164. PubMed ID: 33385856 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]